









Markets
/
Stocks
/
nasdaq-nlsp
/

NLS Pharmaceutics AG

NLSP



View Detailed Chart

2.040USD

-0.020-0.97%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

6.45MMarket Cap

--P/E TTM



NLS Pharmaceutics AG

2.040

-0.020-0.97%

Overview Company Financials Analysis

Analysis

Intraday

30m

Today

-0.97%

5 Days

-5.12%

1 Month

-26.88%

6 Months

+30.77%

Year to Date

-3.32%

1 Year

-62.75%

View Detailed Chart

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

308 / 506

Overall Ranking

597 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.

Undervalued

The company’s latest PE is -0.78, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.40M shares, increasing 26.63% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.